<DOC>
	<DOC>NCT01225965</DOC>
	<brief_summary>To investigate the physical inflammation inhibition effects of EIL (Ectoin-Hydro-Complex) in subjects of the established SALIA-cohort and the preventive effects on lung function decline.</brief_summary>
	<brief_title>Efficacy and Feasibility of EctoinÂ® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Postmenopausal females (75 80 years) FEV1/FVC &lt; 0,77 (in the investigation 2007/2008) Inflammatory markers TFNalpha &gt; median or neutrophilic granulocytes &gt; median (investigation 2007/2008) Non smokers or ex smokers who have stopped smoking for longer than 6 months Participation in another clinical study in the previous month Severe concomitant disease which may have an impact on the study participation Hypersensitivity against Ectoin Myocardial infarction or apoplexy within the last year Uncontrolled hypertension: systolic blood pressure &gt;200 mmHg or diastolic pressure &gt;120 mmHg Known aortic aneurysm Other respiratory diseases (e.g. cystic fibrosis, alpha1Antitrypsin deficiency, sarcoidosis, allergic alveolitis, tuberculosis, etc.) Patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (Inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit) on investigators decision</criteria>
	<gender>Female</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Particulate Matter induced inflammation of the lung</keyword>
</DOC>